Condition
High Risk Acute Lymphoblastic Leukemia
Total Trials
5
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 1 (2)
P 2 (2)
Trial Status
Unknown2
Terminated1
Not Yet Recruiting1
Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06839456Phase 1Recruiting
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
NCT06438796Phase 2Not Yet RecruitingPrimary
Blinatumomab Maintenance After Allo-HSCT
NCT05006040Early Phase 1TerminatedPrimary
HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL
NCT06078306Phase 2Unknown
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).
NCT05066958Phase 1Unknown
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
Showing all 5 trials